Thromboprophylaxis in Head and Neck Microvascular Reconstruction

Manoj Abraham, MD¹ Arvind Badhey, MD² Shirley Hu, MD² Sameep Kadakia, MD²
J. K. Rasamny, MD¹ Augustine Moscatello, MD¹ Yadranko Ducic, MD³

¹ Department of Otolaryngology, New York Medical College, Valhalla, New York

² Department of Otolaryngology-Head and Neck Surgery, New York Eye and Ear Infirmary of Mount Sinai, New York, New York

³ Department of Otolaryngology, Otolaryngology and Facial Plastic Surgery Associates, Fort Worth, Texas

Address for correspondence Sameep Kadakia, MD, Department of Otolaryngology-Head and Neck Surgery, New York Eye and Ear Infirmary of Mount Sinai, 310 East 14th St 6th Floor, New York, NY 10003 (e-mail: sameep8779@gmail.com).

Craniomaxillofac Trauma Reconstruction 2018;11:85–95

Abstract

Head and neck patients undergoing microvascular reconstruction are at high risk for thromboembolism. While the prevention of thromboembolism has become an essential aspect of care, within the field of microsurgery, concern for anastomotic complications have hindered the creation of an accepted regimen. The aim of this review was to evaluate the risks and benefits of prophylactic agents for thromboprophylaxis. A literature search was conducted in MEDLINE, Cochrane Library, and PubMed/NCBI databases. Articles discussing thromboprophylaxis in otolaryngology, head and neck surgery, or microvascular reconstruction were considered in the review from the past 30 years. The majority of patients undergoing microvascular surgery have multiple risk factors for thrombus formation. Several consensus guidelines exist for the prophylaxis in patients who are critically ill, undergoing surgery, or with malignancy. Significant evidence supports the routine use of mechanical means, such as early mobilization and pneumatic compression along with subcutaneous heparin. Low-molecular-weight heparin is also frequently utilized, although results are largely divided. Data on aspirin remain equivocal. Studies on microvascular failure and flap loss have demonstrated little to no association with chemoprophylaxis. The evidence for postoperative thromboprophylaxis regimens in patients undergoing head and neck free tissue transfer is variable. Multiple studies have supported the use of unfractionated heparin or low-molecular-weight heparin. There appears to be an expert consensus for the combined use of mechanical prophylactic methods and chemical prophylaxis. Prospective randomized trials are required to validate the most effective combination of chemoprophylaxis agents.

Keywords

- anticoagulation
- microvascular surgery
- thromboprophylaxis
- head and neck surgery

Postsurgical head and neck cancer (HNC) patients are at increased risk of venous thromboembolism (VTE) and its sequelae, pulmonary embolism (PE).¹ These patients exhibit many of the major risk factors for VTE, including advanced

age, obesity, pulmonary disease, immobility, malignancy, and smoking, and alcohol use.² The incidence of deep vein thrombosis (DVT) in patients with HNC following surgery ranges from 0.07 to 26.3%, although these rates are derived

received

April 23, 2017

accepted after revision

June 17, 2017

published online

October 31, 2017

Copyright © 2018 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.
Tel: +1(212) 584-4662.

DOI <https://doi.org/10.1055/s-0037-1607068>.
ISSN 1943-3875.

from retrospective studies and may underestimate true values.³⁻⁹ In patients undergoing microvascular reconstructive surgery, the risk of VTE is further compounded.

The role of chemoprophylaxis with anticoagulants in patients undergoing microvascular reconstruction is widely debated, as bleeding complications can lead to failure of microvascular reconstruction. Other possible adverse sequelae include airway compromise and wound complications.¹⁰ These risks, along with the perception of low DVT incidence in this population, have been identified as factors contributing to the controversy of routine chemoprophylaxis following microvascular reconstruction of the head and neck.

The prophylactic treatment of DVT and PE has received sparse attention in the otolaryngology literature. There is a paucity of randomized data to guide a standard approach to DVT prophylaxis in patients undergoing free tissue transfer, and management varies widely across institutions and surgeons.

This report is the first critical review of the utility of thromboprophylaxis options in head and neck microvascular reconstruction, in an attempt to develop evidence-based recommendations for thromboprophylaxis. A thorough review of the utility of each agent with respect to thromboprophylaxis and flap survival is presented, followed by suggested recommendations derived from the authors' findings (► **Table 1**).

Methods

We aimed to identify all full-text, peer-reviewed publications pertaining to DVT prophylaxis in otolaryngology or head and neck surgery. The searches were conducted in the Ovid MEDLINE, Cochrane Library, and Google Scholar databases with no language or regional restrictions. The following keywords were used: *venous thrombosis, pulmonary embolism, thromboprophylaxis, mechanical, pneumatic compression, ambulation, mobilization, aspirin, heparin, low-molecular-weight heparin, dextran, and warfarin*. Results were combined with the terms *otolaryngology* and *head and neck* to retrieve articles. All articles addressing thromboprophylaxis in otolaryngology or head and neck surgery were included in the review. The reference lists of these articles were then inspected and any other pertinent publications were added. Where applicable, a search strategy was employed to identify articles discussing thromboprophylaxis in other subspecialties, such as plastic surgery and orthopaedic surgery.

Results

Mechanical Methods

Mechanical methods for thromboprophylaxis include intermittent pneumatic compression (IPC), graduated compression stockings, and venous foot pumps, which have all been demonstrated as safe and effective.¹¹ These devices counteract stasis, one of the three components of Virchow's triad. While multiple authors recommend mechanical means as part of a larger prophylaxis protocol when a patient is at increased risk or as single modality when a patient is considered low risk,^{3,4,6,8,9,12-15} these studies are limited

to retrospective and descriptive reviews that do not critically analyze outcomes in microvascular reconstruction.

In an extensive series of systematic reviews addressing thromboprophylaxis in surgical patients, Roderick et al¹⁶ determined that mechanical methods reduced the risk of DVT by approximately 50% and the risk of PE by 40%. In a recent survey of head and neck cancer surgeons by Garritano and Andrews,¹² IPC was reported as the most common form of prophylaxis in all settings (preoperatively, intraoperatively, and postoperatively). IPC has been shown to decrease the incidence of DVT in patients undergoing head and neck surgical procedures by 60 to 75%.^{8,17} In a retrospective analysis of 12,805 head and neck operations, Moreano et al⁸ identified IPC as one of only two statistically significant independent risk factors for the prevention of DVT. Of note, there were no instances of DVT in patients undergoing microvascular reconstruction in this study. Chen et al⁴ revealed similarly low rates of DVT in their study; all patients had preoperative and postoperative IPC until ambulation and received postoperative anticoagulation with aspirin and LMWH. Another retrospective cohort study of 134 patients who underwent head and neck microvascular reconstruction, however, showed no association between the use of IPC after surgery and reduced risk of DVT.⁹ Importantly, professional groups such as the American College of Chest Physicians (ACCP) and American Society of Clinical Oncology have made official recommendations for DVT prophylaxis that include mechanical therapy. For patients with cancer and an additional risk for DVT, the standard is LMWH in conjunction with mechanical measures.¹¹

While data on postoperative mobilization in patients undergoing major head and neck resection with microvascular reconstruction are limited, the expert consensus is that early monitored mobilization, unless contraindicated (i.e., fibular free flap), should be a key component in a comprehensive thromboprophylactic protocol. Traditionally, concern over vessel thrombosis from vessel kinking due to neck movement resulted in delayed patient mobilization, but there has been no evidence to support or disprove the theory that postoperative mobility affects flap outcomes.¹⁸ A single retrospective cohort study of patients undergoing microvascular reconstruction¹⁹ found that earlier ambulation did not increase flap failure rates and was associated with fewer pulmonary complications. Several authors recommend mobilizing the patient as early as the second postoperative day.^{3,7,8} No studies, however, have shown that time to ambulation predicts the presence of DVT.^{5,9}

Aspirin

The primary role of aspirin in hemostasis is to impair platelet aggregation through the inhibition of thromboxane A2 synthesis and reduce thrombus formation on the surface of a damaged arterial wall.²⁰ Aspirin's effect on venous thrombosis is secondary, as the fibrin-rich red clot formation in venous thrombosis is thought to be driven by the clotting pathway.²¹ However, there is growing evidence that aspirin exerts other antithrombotic effects, including decreasing thrombin generation, attenuating thrombin-mediated coagulant reactions, and increasing fibrin clot permeability and

Table 1 Included relevant studies with varied prophylactic regimen

Author	Year	OCEBM LOE	Patient total cohort breakdown	VTE prophylactic regimen	Study type	Outcomes
Ali et al ³	2015	3b	413 patients undergoing H&N surgery 194 underwent reconstruction	SCDs and BID HSQ	Retrospective cohort study	12 patients developed VTE (all underwent reconstruction) DVT: 3/12 (0.72%) PE: 9/12(2.17%) (3/9 were mortalities)
Ashjian et al ³¹	2007	2b	470 patients 505 microvascular tissue transfers	260: post-op aspirin therapy. 325 mg for 5 d 245: post-op LMWH therapy. 5,000 U daily until ambulating	Prospective database review	No significant difference between two groups. Outcomes: flap thrombosis, flap loss, hematoma, DVT, PE, and death
Bahl et al ²⁹	2014	3b	3,498 post-op otolaryngology patients	2,016: SCDs 1,482: HSQ 5,000 U Q8H(97%)/or LMWH	Retrospective cohort study	Among free tissue transfer patients VTE incidence with chemoppx: 2.1%, bleeding: 11.9% VTE incidence with only SCDs: 7.7%, bleeding: 4.5%
Chen et al ⁴	2008	3b	1,591 patients underwent reconstruction 402 H&N microvascular tissue transfer	SCDs + LMWH + aspirin	Retrospective cohort study	VTE incidence in H&N vs. other areas DVT: 5 HN patients (0.31%). PE: 7 HN (0.44%). H&N patients at increased risk
Chien et al ³³	2005	3b	261 microvascular tissue transfer Regimen of 5,000 U HSQ SC BID and ASA 325 qd	Regimen of 5,000 U HSQ BID + 325 mg aspirin daily	Retrospective cohort study	Complications Flap failures: 6 (2.8%) Venous congestion requiring reexploration: 6 (2.8%) Hematomas: 12 (5.8%)
Clayburgh et al ⁵	2013	2b	100 H&N cancer patients 80% of patients underwent microvascular tissue transfer	No routine chemoprophylaxis Post-op days 2–3 clinical exam and lower extremity ultrasound	Prospective study	Incidence of VTE. 13% (7 DVTs and 1 PE)
Disa ⁶⁴	2003	3b	100 patients underwent microvascular tissue transfer	35: dextran 20 mL/h, 48 32: dextran 20 mL/h, 120 h 27: aspirin 325 mg/d, 120 h	Prospective randomized study	Incidence of systemic complications (CHF, MI, pulmonary edema, pleural effusion, pneumonia) Dextran 48: 29% Dextran 120: 51% Aspirin: 7% No difference in flap outcome
Eley et al ⁵¹	2013	3b	152 patients 173 microvascular tissue transfers	7: Dalteparin 2,500 daily 109: Dalteparin 5,000 daily 37: Dalteparin 5,000 BID 20: Dalteparin 7,500 or more daily	Retrospective cohort study	Distribution of unexplained hematoma was similar for all doses Dose increase does not increase risk for bleeding
Karimi et al ⁵⁸	2016	2b	30 patients underwent microvascular tissue transfer 100 mg/d ASA for 5 d and enoxaparin 40 mg/d SC for 3 d	100 mg aspirin daily × 5 d + 40 mg subcutaneous enoxaparin daily × 3 d	Interventional prospective study	Flap success rate was 100%. Reexploration in 3 patients

(Continued)

Table 1 (Continued)

Author	Year	OCEBM LOE	Patient total cohort breakdown	VTE prophylactic regimen	Study type	Outcomes
Kakei et al ⁷	2016	3b	133 patients 81 underwent microvascular tissue transfer	No chemoppx Bilateral venous duplex ultrasound, post-op day 2	Retrospective cohort study	Incidence of VTE: 26.3% DVT alone: 24% DVT + PE: 2.3%
Lighthall et al ¹⁵	2013	2b	390 microvascular tissue transfers	184: SCDs + early ambulation 142: aspirin 25: low-molecular-weight heparin 16: heparin gtt 23: aspirin + LMWH	Prospective database review	No difference in complications (flap loss, infection, seroma, fistula, hematoma) aspirin vs. no anticoagulation
Moreano et al ⁸	1998	3b	12,805 operations		Retrospective cohort study	34 patients with post-op DVT (0.3%). 24/34 had PE (0.2%) 12: no ppx 22: SCDs
Reiter et al ⁵⁹	2012	3b	137 microvascular tissue transfers	Low thrombosis risk: 20 mg enoxaparin daily Medium/high thrombosis risk: 40 mg enoxaparin daily	Retrospective cohort study	Overall flap survival was 97.1%
Shuman et al ⁸⁴	2012	3b	2,016 patients	No chemoppx + SCDs	Retrospective cohort study	30 d VTE 1.3%. Caprini score: <7 = 0.5% 7/8 = 2.4% >8 = 18.3% Mean score for patients with VTE (7.4) significantly higher than no VTE (4.8)
Thai et al ⁹	2013	3b	134 patients underwent microvascular reconstruction		Retrospective cohort study	End point of confirmed/suspicious VTE within 30 d post-op 2 (1.4%) 1 PE/1 DVT confirmed VTE 6 (4.4%) suspicious VTE (acute respiratory failure, sudden)

Abbreviations: ASA, acetylsalicylic acid; BID, twice a day; chemoppx, chemoprophylaxis; CHF, congestive heart failure; DVT, deep vein thrombosis; H&N, head and neck; HSQ, subcutaneous heparin; MI, myocardial infarction; OCEBM LOE, Oxford Centre for Evidence-Based Medicine levels of evidence; PE, pulmonary embolism; ppx, prophylaxis; qd, every day; SCDs, sequential compression device; VTE, venous thromboembolism.

enhanced clot lysis.²⁰ Murine models have also shown that platelets may be an important component of early DVT. Two trials, the Warfarin and Aspirin (WARFASA) study²² and the Aspirin to Prevent Recurrent Venous Thromboembolism (ASPIRE) study,²³ found a decrease in recurrent VTE with a low risk of major bleeding in patients with idiopathic VTE.²¹

Despite this, few studies have evaluated the direct impact of aspirin on DVT outcomes in patients undergoing head and neck reconstruction. Authors more frequently describe its utilization in preventing microvascular thrombosis. Studies have shown that a platelet thrombus can occlude even a technically perfect anastomosis,²⁴ and thus antiplatelet therapy may play a preventive role.^{25,26}

In a survey of academic otolaryngology departments, Spiegel and Polat²⁷ reported that 76.5% of microvascular surgeons were using aspirin, although no delineation was made whether prevention of anastomotic thrombosis or VTE was the goal. In a prospective study of 115 patients undergoing head and neck microvascular reconstruction, Blackwell reported no incidence of DVT or PE with the use of mechanical thromboprophylaxis and postoperative low-dose aspirin as the only chemoprophylactic agent.²⁸ However, the ACCP does not recommend using aspirin alone as thromboprophylaxis against DVT in any patient population, primarily because more effective agents are available, such as unfractionated heparin (UFH) and LMWH.²

Both a recent meta-analysis of the efficacy of antithrombotic regimens in microsurgery and a retrospective study of 3,498 patients undergoing otolaryngologic surgery concluded that aspirin increases the risk of hematoma significantly.^{29,30} Other studies have demonstrated no such increase^{15,28,31} when comparing aspirin to no prophylaxis.^{22,32} Chien et al³³ found similar hematoma rates between the use of aspirin and HSQ and other anticoagulation agents in a retrospective chart review of 261 patients undergoing free tissue transfer, although this comparison was not made with an internal arm. In a retrospective study of 470 microvascular patients, Ashjian et al³¹ found no difference in complication rates, including DVT and microvascular thrombosis, between patients treated with postoperative aspirin and those treated with LMWH. The concurrent use of aspirin and another anticoagulant has been found to be significantly associated with increased bleeding complications, potentially due to the simultaneous blockage of both the cellular, platelet-mediated clotting mechanism and the humoral clotting cascade.^{10,29,32}

Importantly, aspirin has not been shown to be superior to other regimens or effective as a single prophylaxis drug for flap survival.^{15,33} One study evaluating microvascular reconstructive surgery without antithrombotic agents showed no flap failure secondary to thrombosis and concluded that the use of chemoprophylaxis alone does not seem to significantly affect the patency of microvascular structures.³⁴

Unfractionated Heparin Formulations

UFH is a polyglycosaminoglycan that inhibits the coagulation cascade by inactivating downstream coagulation factors and platelet aggregation, primarily through increased antithrombin III antiprotease activity. Its effect is measured clinically

with activated partial thromboplastin time, but the dose-response relationship can be unpredictable, requiring high-dose titration.^{35,36}

Subcutaneous Heparin

Recent departmental surveys in otolaryngology have demonstrated that 26.5% of surgeons use heparin, typically postoperatively in the subcutaneous form.²⁷ In other fields of microsurgery, subcutaneous heparin (HSQ) is the most commonly used anticoagulant in clinical practice.³⁷

Similar to studies conducted on other anticoagulants, the otolaryngology literature focuses on flap survival and hematoma rather than DVT prevention.³⁸ Motakef et al³⁸ concluded that the use of HSQ is an efficacious option for thromboprophylaxis in microsurgery, and a range of doses have been proven safe (5,000 U once, twice, or three times daily), although there is no true consensus on dose, duration, or initiation of therapy.^{33,39} Stockmans et al demonstrated that higher doses of HSQ can be more effective in preventing VTE but may come with an increased incidence of bleeding.³⁷

Most of the existing literature demonstrate that HSQ is not associated with an increase in adverse flap outcomes.^{30,31,40,41} The landmark multicenter prospective study on head and neck microsurgery by Khouri et al, one of the only level-I evidence studies addressing anticoagulation protocols, demonstrated that only HSQ had a significant protective effect on flap thrombosis.²⁵ A recent review by Fan et al concluded that there are insufficient data to refute this evidence.⁴² A recent meta-analysis evaluating the efficacy of thromboprophylactic agents used in microsurgery concluded that HSQ reduced the risk of flap loss by 35% but raised the risk of hematoma, though these differences were significant.³⁰ In a retrospective review of 470 patients undergoing free tissue transfer, HSQ was found to be a safe agent that did not increase the risk of postoperative bleeding, hematoma, or flap failure.³¹ A meta-analysis conducted by Pan et al analyzing large-scale retrospective studies of anticoagulation regimens in microvascular reconstruction demonstrated that the flap loss rate is similar when heparin or aspirin is used.⁴¹ A review of the free flap literature from 1996 to 2005 recommended that anticoagulation, preferably with heparin, was a required part of postoperative management.⁴⁰

Recently, a Cochrane review was conducted comparing LMWH to HSQ for perioperative thromboprophylaxis for patients with cancer and found no significant difference in outcomes between the agents.⁴³ In their retrospective cohort study, Bahl et al⁴⁴ showed that patients undergoing free tissue transfer reduced their incidence of DVT from 7.7 to 2.1% but increased their bleeding complications from 4.5 to 11.9% when receiving chemoprophylaxis consisting of either HSQ or LMWH. Importantly, increased bleeding was associated with concomitant usage of antiplatelet medications and anticoagulants. This study, however, did not evaluate the difference in effect between HSQ and LMWH, and patients were also treated with various antiplatelet and perioperative chemoprophylactic agents, thus making results difficult to interpret.⁴⁴

HSQ is an efficacious option for perioperative DVT prophylaxis that is widely used, and no prospective or large-scale

studies have demonstrated a detrimental effect of heparin compared with other agents regarding flap survival.

Intravenous Heparin

Intravenous (IV) heparin is the primary treatment for active VTE. No trials or reviews exist demonstrating the use of a heparin infusion for VTE prevention in head and neck surgery. However, its role in flap thromboprophylaxis is better described. Several studies have shown that patients treated with heparin drips following free tissue transfer surgery had significantly increased complications, including flap loss and hematoma/hemorrhage, compared with those who did not receive prophylaxis.¹⁵ Kroll et al described the use of a continuous heparin infusion and concluded that doses above 500 U/hour increase significantly the risk of hematoma.⁴⁵ Nelson et al compared the use of an intraoperative heparin bolus and postoperative heparin infusion to HSQ in 23 hypercoagulable patients undergoing microsurgery. The cohort treated with IV heparin had clinically lower rates of VTE and flap loss but an increased risk for postoperative bleeding, hematoma, and anemia.⁴⁶

Low-Molecular-Weight Heparins

LMWH is a fragmented heparin derivative with a more specific inhibitory effect on factor X and a less systemic effect on antithrombin activity.

Within the DVT literature, there have been multiple studies demonstrating LMWH to be at least as effective as UFH for thromboprophylaxis.⁴³ This, along with a favorable risk profile initially demonstrated by Malm et al⁴⁷ in an animal model study on surgical bleeding rates, has made LMWH a practice-changing treatment strategy. LMWH has a more predictable dose–response relationship, greater bioavailability, and longer-half life and is thus preferable for high-risk patients.^{48,49} The ACCP recommends either LMWH or low-dose UFH for high-risk patients undergoing general surgery and LMWH only for patients undergoing high-risk orthopaedic surgery.¹¹ Increased dosing of LMWH in patients who are at high risk, such as those with malignancy or undergoing microvascular reconstruction, has also been recommended.⁵⁰

Currently, factor Xa levels are being used to modulate therapy. Eley et al⁵¹ concluded that there was a high incidence of subtherapeutic anti-Xa levels in response to standard prophylactic doses of dalteparin in 153 head and neck microvascular patients but showed success in dose adjustment of LMWH by using anti-Xa concentrations to titrate a standard 2,500 U dose to therapeutic concentrations. However, the accuracy of such measurements may be variable, as levels must be drawn exactly after LMWH is administered.⁵¹ There also exist multiple formulations of LMWH in the market, making standardization more difficult.^{52,53}

Similar to other agents, there are no studies designed specifically to evaluate DVT outcomes in free tissue transfer patients treated with LMWH. The orthopaedic literature cites several trials demonstrating that LMWH reduces the incidence of DVT in hip replacement surgery by 31 to 79% compared with placebo and is as effective or more effective than HSQ.^{54,55} One randomized controlled trial of 665 patients undergoing hip

replacement showed fewer bleeding events in patients given LMWH (30 mg twice daily) compared with HSQ (7,500 U twice daily) and no difference compared with placebo.⁵⁶ In a randomized prospective study of critical patients undergoing major surgery, LMWH (40 mg once daily) and HSQ (5,000 U twice daily) were found to be equivalent as prophylaxis against DVT; UFH did result in a greater risk of hematoma.⁴⁹ A meta-analysis of general surgery patients treated with LMWH showed a lesser incidence of PE but a trend toward an increase in bleeding complications.⁴⁸ In a study of 225 patients following breast microvascular reconstruction, Lemaine et al showed a 3.4% incidence of clinically silent DVT and a 1.9% rate of flap loss with LMWH.⁵⁷

Multiple studies have addressed the effect of LMWH on flap outcomes. In a study of 30 head and neck microvascular patients, Karimi et al demonstrated the utility of a combination protocol of aspirin and enoxaparin for 5 and 3 days, respectively, for flap survival, with no incidence of flap loss or hematoma.⁵⁸ A retrospective study of 137 microvascular reconstruction patients demonstrated that LMWH is an effective standalone antithrombotic, with outcomes comparable to those of HSQ and aspirin studies and a flap survival rate of 97.1%.⁵⁹ In a study of 153 microvascular head and neck patients receiving prophylactic doses of dalteparin with or without aspirin, there were six events of hematoma, and this risk was not influenced by the dose of dalteparin or addition of aspirin.⁵¹ In a systematic review by Pršić et al,⁶⁰ attention is drawn to the conflicting results of studies on LMWH for flap thrombosis, with some demonstrating equal if not better outcomes than HSQ, such as decreased rate of bleeding, and others showing it to be significantly inferior.

To date, there is an ongoing debate in the literature regarding LMWH, but an improved risk profile and the potential of decreased bleeding compared with UFH make this agent a viable thromboprophylactic option in head and neck microvascular surgery, particularly for patients in whom HSQ is contraindicated or who possess high-risk factors requiring a more aggressive thromboprophylactic regimen.

Dextran

While no data have been reported on the use of dextran for systemic DVT, multiple studies have focused on microvascular thromboprophylaxis.

Dextran, by impairing platelet function, prolonging bleeding time, and destabilizing fibrin polymerization, has been shown to reduce the incidence of microanastomotic thrombosis in multiple animal models.^{61–63} However, results from clinical studies have largely suggested that dextran has no bearing on the success rates of free tissue transfer in head and neck reconstruction^{64–68} and may even increase flap loss.⁴⁵ A recent large study by Riva et al,⁶⁷ comparing three groups of patients in which prostaglandin-E1, dextran 40, and no prophylaxis were given, concluded that neither PGE1 nor dextran benefits flap survival. In a prospective randomized trial, Disa et al⁶⁴ determined that there was no difference in overall flap survival between dextran and aspirin use.

Serious complications of dextran have been reported in the literature, such as bleeding diatheses in children, osmotic

complications, pulmonary edema, cerebral edema, nephrotoxicity, and fatal anaphylaxis.^{69–73} Disa et al⁶⁴ concluded that patients receiving dextran had up to a 7.2 greater relative risk of developing an adverse cardiac or pulmonary event, especially acute respiratory distress syndrome, when compared with patients receiving aspirin. The frequency of systemic complications was also shown to correlate positively with the duration of dextran use. Jayaprasad et al⁶⁵ reported a statistically significant increase in postoperative atelectasis but no other local or systemic complications. Fan et al identified level-I evidence showing dextran to increase systemic complications.⁴² Despite this, a questionnaire conducted in 2007 among head and neck surgeons in the United Kingdom demonstrated that 45% of respondents use dextran routinely and nearly 20% combine it with other antithrombotic agents such as aspirin and heparin.⁶⁶

Studies assessing the efficacy of dextran as DVT prophylaxis in orthopaedic procedures can also inform its potential utility in head and neck microvascular reconstructive surgery. In their systematic review evaluating various methods of thromboprophylaxis, Roderick et al¹⁶ ascertained that dextran decreases the risk of DVT by approximately 50% regardless of the type of surgery, but no reliable conclusions could be drawn regarding PE. Dextran appeared to be less effective in preventing DVT than the heparin regimens employed in the included studies.^{74–76} Dextran was also associated with an increased risk of bleeding. One study conducted in geriatric hip fracture patients showed that aspirin and dextran are equally effective thromboembolic prophylactic agents.⁷⁷

Warfarin

The use of warfarin as DVT prophylaxis is not described in any study. It is a mainstay of treatment only once DVT is established.

Inferior Vena Cava Filter

No literature exists on the use of inferior vena cava (IVC) filters for VTE prophylaxis in head and neck surgery. IVC filters are indicated in patients with proven thromboembolic disease and with contraindications to anticoagulation, complications of anticoagulation, or recurrent VTE.⁷⁸

Discussion

A majority of otolaryngology patients undergoing microvascular reconstruction possess all three cardinal factors of Virchow's triad—venous stasis secondary to prolonged operations especially when involving free tissue transfer, hypercoagulability as a result of malignancy, and endothelial damage from tumor resection and tissue harvesting.⁷⁹ The exact occurrence of DVT in these patients has, however, been debated and inadequately addressed. A retrospective study of 1,018 patients who underwent HNC surgery reported no VTE events and 12 bleeding complications, 11 of which occurred in patients who received chemoprophylaxis, and concluded that chemoprophylaxis should not be routinely used.⁸⁰ A recent systematic review of 23 articles encompassing 618,264 otolaryngology surgery patients showed a VTE incidence of 0.4% and concluded

that chemoprophylaxis did not decrease the risk of VTE but increased the risk of bleeding.⁸¹ On the other hand, the greatest incidence of DVT has been shown to occur in patients undergoing comprehensive resection with reconstruction.^{3,5,7} One study demonstrated a fourfold increase in DVT in patients undergoing head and neck reconstruction.⁴

The role of chemoprophylaxis with anticoagulants in patients undergoing microvascular reconstruction is particularly challenging, given the potential failure of microvascular reconstruction from bleeding or hematoma. Other possible adverse sequelae include airway compromise and wound complications.¹⁰ These risks, along with the perception of low DVT incidence in this population, have been identified as factors contributing to the controversy of routine chemoprophylaxis following microvascular reconstruction of the head and neck. Ah-See et al⁸² reported in 1997 that a majority of otolaryngologists do not employ any form of DVT prophylaxis, although more recent studies have shown an increase in the practice.

VTE thromboprophylaxis protocols in head and neck microvascular reconstruction have received sparse attention in the otolaryngology literature. Many studies¹³ focus only on the effects of chemoprophylaxis on outcomes of free tissue transfer, and there are no long-term studies addressing the incidence of DVT. However, a recent systematic review and meta-analysis opined that no postoperative antithrombotic regimen has shown significant benefits for flap survival.³⁰ Therefore, there is a need to shift focus to VTE prevention. If an effective VTE prophylactic regimen demonstrates typical flap survival, it should be adopted as a standard of care.

Microvascular surgeons have experimented with various regimens, many of which are a combination of the methods used in previous randomized controlled trials in other patient populations and expert opinion. The armamentarium encompasses IPC, early ambulation, aspirin, HSQ, LMWH, systemic anticoagulation, dextran, and IVC filters. Agents used in chemoprophylaxis target the coagulation cascade primarily (→Fig. 1). The coagulation cascade has two pathways, intrinsic and extrinsic, that are a series of reactions in which an inactive serine protease and its glycoprotein cofactor are activated and subsequently catalyze the next reaction in the cascade, ultimately leading to cross-linked fibrin.⁸³

The importance of developing a reliable tool for stratifying DVT risk cannot be overemphasized, as it can guide subsequent aggressiveness of postoperative thromboprophylaxis. One method for stratifying the risk of DVT that is often described in the literature is the Caprini risk assessment model,^{9,44,84} which uses a point scoring system for approximately 40 risk factors. The Caprini risk assessment tool has been validated in both retrospective and prospective studies for patients undergoing elective general surgery and modified for use in plastic surgery patients.^{44,85} Studies have consistently shown that patients with a high Caprini risk score have a higher rate of DVT.^{5,7,44,84} Two studies have also demonstrated its effectiveness for identifying patients with low, moderate, and high risk for DVT within 30 days after surgery.^{44,84} However, results often did not reach statistical significance.^{5,9,44}

Fig. 1 Schematic of the coagulation cascade and target areas of chemoprophylactic agents. (We thank Jill Gregory for providing this artwork. This piece has been used with permission from the Mount Sinai Health System).

There are caveats to the routine use of early ambulation and mechanical methods such as IPC. Specifically, patients undergoing fibula tissue transfer are likely to be immobilized for a period of time following surgery. In addition, IPC is contraindicated on the donor limb. Other adjunct therapies may thus be warranted in these patients who are at higher risk for DVT. When anticoagulation is precluded, such as in patients with bleeding diathesis, hemorrhagic stroke, or complications of anticoagulation, an IVC filter may play an important role.⁸⁶

There is a lack of substantial evidence to show that drugs used to primarily treat local thrombosis (aspirin, dextran) are also able to reduce the risk of DVT/PE as effectively as other thromboprophylactic medications (HSQ, LMWH), especially when utilized in single pharmacotherapy regimens. However, several studies have concluded that a combination of aspirin and a systemic anticoagulant, while effective in DVT prevention, may increase the rate of hematoma. Thus, the combined use of aspirin and an anticoagulant must be approached cautiously. Analysis of the current studies that exist in the microvascular, head and neck, and otolaryngology literature shows most evidence for the use of HSQ and mechanical prophylaxis, with at least equivalent flap survival rates compared with no chemoprophylaxis.

Meta-analyses comparing UFH and LMWH have shown both agents to be effective as primary VTE prophylaxis.⁸⁷ Both the ACCP and the American Society of Clinical Oncology endorse routine chemoprophylaxis with LMWH in cancer

patients undergoing surgery, who are at increased risk for VTE.⁸⁸ Studies are currently focusing on the superiority of LMWH over UFH for general thromboprophylaxis.⁸⁹ In addition, new clinical studies have proposed continuation of LMWH thromboprophylaxis for up to 3 weeks after discharge, which may reduce the rate of late DVT by 60%.⁸⁷ There may also be a unique role for LMWH in patients with no risk factors for bleeding, a history of heparin-induced thrombocytopenia, or active VTE. However, more studies specific to head and neck microvascular reconstruction need to be conducted before official recommendations are made regarding LMWH.

Novel agents are being presented regularly to improve both flap survival and patient outcomes in microvascular surgery. Pršić et al supported the use of statins as part of the perioperative regimen for patients undergoing microvascular reconstruction.⁶⁰ Wikner et al studied the role of thromboelastometry in microsurgery.⁹⁰ Thromboelastometry is a viscoelastic hemostatic assay that provides a graphical evaluation of the kinetics of clot formation, ideally allowing distinction between a surgical etiology of bleeding and coagulopathy, diagnosis of the type of coagulopathy, and guidance in treatment.^{91–93} Both of these examples suggest how perioperative free flap management protocols may evolve in the future.

The ideal study of randomizing patients to different anticoagulation regimens and analyzing VTE and free tissue transfer survival outcomes has yet to be performed. Thus, this assessment is based on the most meaningful conclusions drawn from

studies that do exist. The regimens with the most consistent support in the literature are HSQ, mechanical methods, and early mobilization. Aspirin and dextran have not been shown to aid in microvascular flap survival, and their role in VTE prophylaxis is equivocal; a stratified, patient-specific risk-benefit analysis should thus be considered. LMWH has demonstrated effectiveness in specific patient populations and its use as chemoprophylaxis in patients undergoing microvascular reconstructive surgery is increasing. Ultimately, more controlled studies comparing both individual agents and no prophylaxis must be conducted.

Conclusion

There is a clear need for a consistent chemoprophylaxis protocol for patients undergoing microvascular reconstruction. While many agree therapy should be tailored to the individual patient, the establishment of consensus guidelines similar to those recommended by the ACCP among those specializing in the field would improve patient management. As microvascular reconstruction is becoming a more successful and common procedure, evidence must now be applied to the art.

Most data in the literature support the routine use of HSQ and mechanical methods as VTE prophylaxis. HSQ and aspirin are commonly used in tandem, but there is evidence that combining antithrombotic agents increases the rate of complications and aspirin alone does not increase flap survival. There have been recent studies demonstrating the efficacy, safety, and decreased risk of bleeding with LMWH, which may have a role in more vulnerable populations, but the literature is insufficient to recommend its use across all head and neck microvascular reconstructive surgery. Multi-institutional, randomized clinical trials with controls must be conducted to corroborate the conclusions presented in this review article.

Conflict of Interest

This article has not been/nor is being considered for publication elsewhere. There are no financial disclosures or conflicts of interest.

Acknowledgment

We thank Jill Gregory, Senior Medical Illustrator, from the Mount Sinai Health System for providing artwork for this project.

References

- 1 Agnelli G. Prevention of venous thromboembolism in surgical patients. *Circulation* 2004;110(24, Suppl 1):IV4-IV12
- 2 Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest* 2004;126(3, Suppl):338S-400S
- 3 Ali NS, Nawaz A, Junaid M, Kazi M, Akhtar S. Venous thromboembolism-incidence of deep venous thrombosis and pulmonary embolism in patients with head and neck cancer: a tertiary care experience in Pakistan. *Int Arch Otorhinolaryngol* 2015;19(03):200-204
- 4 Chen CM, Disa JJ, Cordeiro PG, Pusic AL, McCarthy CM, Mehrara BJ. The incidence of venous thromboembolism after oncologic head and neck reconstruction. *Ann Plast Surg* 2008;60(05):476-479
- 5 Clayburgh DR, Stott W, Cordiero T, et al. Prospective study of venous thromboembolism in patients with head and neck cancer after surgery. *JAMA Otolaryngol Head Neck Surg* 2013;139(11):1143-1150
- 6 Garritano FG, Lehman EB, Andrews GA. Incidence of venous thromboembolism in otolaryngology-head and neck surgery. *JAMA Otolaryngol Head Neck Surg* 2013;139(01):21-27
- 7 Kakei Y, Akashi M, Hasegawa T, Minamikawa T, Usami S, Komori T. Incidence of venous thromboembolism after oral oncologic surgery with simultaneous reconstruction. *J Oral Maxillofac Surg* 2016;74(01):212-217
- 8 Moreano EH, Hutchison JL, McCulloch TM, Graham SM, Funk GF, Hoffman HT. Incidence of deep venous thrombosis and pulmonary embolism in otolaryngology-head and neck surgery. *Otolaryngol Head Neck Surg* 1998;118(06):777-784
- 9 Thai L, McCarn K, Stott W, et al. Venous thromboembolism in patients with head and neck cancer after surgery. *Head Neck* 2013;35(01):4-9
- 10 Pugh CM, Dennis RH II, Massac EA. Evaluation of intraoperative anticoagulants in microvascular free-flap surgery. *J Natl Med Assoc* 1996;88(10):655-657
- 11 Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 2012;141(2, Suppl):e227S-e277S
- 12 Garritano FG, Andrews GA. Current practices in venous thromboembolism prophylaxis in otolaryngology-head and neck surgery. *Head Neck* 2016;38(Suppl 1):E341-E345
- 13 Innis WP, Anderson TD. Deep venous thrombosis and pulmonary embolism in otolaryngologic patients. *Am J Otolaryngol* 2009;30(04):230-233
- 14 Lee J, Alexander A, Higgins K, Geerts W. The Sunnybrook experience: review of deep vein thrombosis and pulmonary embolism in otolaryngology. *J Otolaryngol Head Neck Surg* 2008;37(04):547-551
- 15 Lighthall JG, Cain R, Ghanem TA, Wax MK. Effect of postoperative aspirin on outcomes in microvascular free tissue transfer surgery. *Otolaryngol Head Neck Surg* 2013;148(01):40-46
- 16 Roderick P, Ferris G, Wilson K, et al. Towards evidence-based guidelines for the prevention of venous thromboembolism: systematic reviews of mechanical methods, oral anticoagulation, dextran and regional anaesthesia as thromboprophylaxis. *Health Technol Assess* 2005;9(49):iii-iv, ix-x, 1-78
- 17 Clagett GP, Anderson FA Jr, Levine MN, Salzman EW, Wheeler HB. Prevention of venous thromboembolism. *Chest* 1992;102(4, Suppl):391S-407S
- 18 Kruse AL, Luebbbers HT, Grätz KW, Obwegeser JA. Factors influencing survival of free-flap in reconstruction for cancer of the head and neck: a literature review. *Microsurgery* 2010;30(03):242-248
- 19 Yeung JK, Harrop R, McCreary O, et al. Delayed mobilization after microsurgical reconstruction: an independent risk factor for pneumonia. *Laryngoscope* 2013;123(12):2996-3000
- 20 Undas A, Brummel-Ziedins KE, Mann KG. Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions. *Blood* 2007;109(06):2285-2292
- 21 Wakefield TW, Obi AT, Henke PK. An aspirin a day to keep the clots away: can aspirin prevent recurrent thrombosis in extended treatment for venous thromboembolism? *Circulation* 2014;130(13):1031-1033
- 22 Becattini C, Agnelli G, Schenone A, et al; WARFASA Investigators. Aspirin for preventing the recurrence of venous thromboembolism. *N Engl J Med* 2012;366(21):1959-1967
- 23 Brighton TA, Eikelboom JW, Mann K, et al; ASPIRE Investigators. Low-dose aspirin for preventing recurrent venous thromboembolism. *N Engl J Med* 2012;367(21):1979-1987

- 24 Johnson PC, Barker JH. Thrombosis and antithrombotic therapy in microvascular surgery. *Clin Plast Surg* 1992;19(04):799–807
- 25 Khouri RK, Cooley BC, Kunselman AR, et al. A prospective study of microvascular free-flap surgery and outcome. *Plast Reconstr Surg* 1998;102(03):711–721
- 26 Li X, Cooley BC. Effect of anticoagulation and inhibition of platelet aggregation on arterial versus venous microvascular thrombosis. *Ann Plast Surg* 1995;35(02):165–169, discussion 169–170
- 27 Spiegel JH, Polat JK. Microvascular flap reconstruction by otolaryngologists: prevalence, postoperative care, and monitoring techniques. *Laryngoscope* 2007;117(03):485–490
- 28 Blackwell KE. Unsurpassed reliability of free flaps for head and neck reconstruction. *Arch Otolaryngol Head Neck Surg* 1999;125(03):295–299
- 29 Bahl V, Shuman AG, Hu HM, et al. Chemoprophylaxis for venous thromboembolism in otolaryngology. *JAMA Otolaryngol Head Neck Surg* 2014;140(11):999–1005
- 30 Lee KT, Mun GH. The efficacy of postoperative antithrombotics in free flap surgery: a systematic review and meta-analysis. *Plast Reconstr Surg* 2015;135(04):1124–1139
- 31 Ashjian P, Chen CM, Pusic A, Disa JJ, Cordeiro PG, Mehrara BJ. The effect of postoperative anticoagulation on microvascular thrombosis. *Ann Plast Surg* 2007;59(01):36–39, discussion 39–40
- 32 Dort JC, Farwell DG, Findlay M, et al. Optimal perioperative care in major head and neck cancer surgery with free flap reconstruction: a consensus review and recommendations from the enhanced recovery after surgery society. *JAMA Otolaryngol Head Neck Surg* 2017;143(03):292–303
- 33 Chien W, Varvares MA, Hadlock T, Cheney M, Deschler DG. Effects of aspirin and low-dose heparin in head and neck reconstruction using microvascular free flaps. *Laryngoscope* 2005;115(06):973–976
- 34 Veravuthipakorn L, Veravuthipakorn A. Microsurgical free flap and replantation without antithrombotic agents. *J Med Assoc Thai* 2004;87(06):665–669
- 35 Kumar S, Moorthy R. New oral anticoagulants – a guide for ENT surgeons. *J Laryngol Otol* 2016;130(04):324–328
- 36 Askari M, Fisher C, Weniger FG, Bidic S, Lee WP. Anticoagulation therapy in microsurgery: a review. *J Hand Surg Am* 2006;31(05):836–846
- 37 Stockmans F, Stassen JM, Vermeylen J, Hoylaerts MF, Nyström A. A technique to investigate microvascular mural thrombus formation in arteries and veins: II. Effects of aspirin, heparin, r-hirudin, and G-4120. *Ann Plast Surg* 1997;38(01):63–68
- 38 Motakef S, Mountziaris PM, Ismail IK, Agag RL, Patel A. Emerging paradigms in perioperative management for microsurgical free tissue transfer: review of the literature and evidence-based guidelines. *Plast Reconstr Surg* 2015;135(01):290–299
- 39 Xipoleas G, Levine E, Silver L, Koch RM, Taub PJ. A survey of microvascular protocols for lower-extremity free tissue transfer I: perioperative anticoagulation. *Ann Plast Surg* 2007;59(03):311–315
- 40 Lecoq JP, Senard M, Hartstein GM, Lamy M, Heymans O. Thromboprophylaxis in microsurgery. *Acta Chir Belg* 2006;106(02):158–164
- 41 Pan XL, Chen GX, Shao HW, Han CM, Zhang LP, Zhi LZ. Effect of heparin on prevention of flap loss in microsurgical free flap transfer: a meta-analysis. *PLoS One* 2014;9(04):e95111
- 42 Fan KL, Patel KM, Mardini S, Attinger C, Levin LS, Evans KK. Evidence to support controversy in microsurgery. *Plast Reconstr Surg* 2015;135(03):595e–608e
- 43 Akl EA, Kahale L, Sperati F, et al. Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer. *Cochrane Database Syst Rev* 2014;(06):CD009447
- 44 Bahl V, Hu HM, Henke PK, Wakefield TW, Campbell DA Jr, Caprini JA. A validation study of a retrospective venous thromboembolism risk scoring method. *Ann Surg* 2010;251(02):344–350
- 45 Kroll SS, Miller MJ, Reece GP, et al. Anticoagulants and hematomas in free flap surgery. *Plast Reconstr Surg* 1995;96(03):643–647
- 46 Nelson JA, Chung CU, Bauder AR, Wu LC. Prevention of thrombosis in hypercoagulable patients undergoing microsurgery: a novel anticoagulation protocol. *J Plast Reconstr Aesthet Surg* 2017;70(03):307–312
- 47 Malm K, Dahlbäck B, Arnljots B. Low-molecular-weight heparin (dalteparin) effectively prevents thrombosis in a rat model of deep arterial injury. *Plast Reconstr Surg* 2003;111(05):1659–1666
- 48 Green D, Hirsh J, Heit J, Prins M, Davidson B, Lensing AW. Low molecular weight heparin: a critical analysis of clinical trials. *Pharmacol Rev* 1994;46(01):89–109
- 49 De A, Roy P, Garg VK, Pandey NK. Low-molecular-weight heparin and unfractionated heparin in prophylaxis against deep vein thrombosis in critically ill patients undergoing major surgery. *Blood Coagul Fibrinolysis* 2010;21(01):57–61
- 50 Blackburn TK, Java KR, Lowe D, Brown JS, Rogers SN. Safety of a regimen for thromboprophylaxis in head and neck cancer microvascular reconstructive surgery: non-concurrent cohort study. *Br J Oral Maxillofac Surg* 2012;50(03):227–232
- 51 Eley KA, Parker RJ, Watt-Smith SR. Low molecular weight heparin in patients undergoing free tissue transfer following head and neck ablative surgery: review of efficacy and associated complications. *Br J Oral Maxillofac Surg* 2013;51(07):610–614
- 52 Mulloy B, Hogwood J, Gray E, Lever R, Page CP. Pharmacology of heparin and related drugs. *Pharmacol Rev* 2016;68(01):76–141
- 53 Nader HB, Walenga JM, Berkowitz SD, Ofosu F, Hoppensteadt DA, Cella G. Preclinical differentiation of low molecular weight heparins. *Semin Thromb Hemost* 1999;25(Suppl 3):63–72
- 54 Planes A, Vochelle N, Darmon JY. Out-of-hospital prophylaxis with low-molecular-weight heparin in hip surgery: the French study–venographic outcome at 35 days. *Chest* 1998;114(2, Suppl Evidence):125S–129S
- 55 Spiro TE, Johnson GJ, Christie MJ, et al; Enoxaparin Clinical Trial Group. Efficacy and safety of enoxaparin to prevent deep venous thrombosis after hip replacement surgery. *Ann Intern Med* 1994;121(02):81–89
- 56 Levine MN, Hirsh J, Gent M, et al. Prevention of deep vein thrombosis after elective hip surgery. A randomized trial comparing low molecular weight heparin with standard unfractionated heparin. *Ann Intern Med* 1991;114(07):545–551
- 57 Lemaine V, McCarthy C, Kaplan K, et al. Venous thromboembolism following microsurgical breast reconstruction: an objective analysis in 225 consecutive patients using low-molecular-weight heparin prophylaxis. *Plast Reconstr Surg* 2011;127(04):1399–1406
- 58 Karimi E, Ardestani SH, Jafari M, Haghighi AB. Testing a new anticoagulation method for free flap reconstruction of head and neck cancers. *Clin Exp Otorhinolaryngol* 2016;9(04):370–373
- 59 Reiter M, Kapsreiter M, Betz CS, Harréus U. Perioperative management of antithrombotic medication in head and neck reconstruction—a retrospective analysis of 137 patients. *Am J Otolaryngol* 2012;33(06):693–696
- 60 Pršić A, Kiwanuka E, Caterson SA, Caterson EJ. Anticoagulants and statins as pharmacological agents in free flap surgery: current rationale. *Eplasty* 2015;15:e51
- 61 Salemark L, Wieslander JB, Dougan P, Arnljots B. Studies of the antithrombotic effects of dextran 40 following microarterial trauma. *Br J Plast Surg* 1991;44(01):15–22
- 62 Scholz T, Evans GR. Impact of hypertonic and hyperoncotic saline solutions on ischemia-reperfusion injury in free flaps. *Plast Reconstr Surg* 2008;122(01):85–94
- 63 Wieslander JB, Dougan P, Stjernquist U, Aberg M, Bergentz SE. The influence of dextran and saline solution upon platelet behavior after microarterial anastomosis. *Surg Gynecol Obstet* 1986;163(03):256–262

- 64 Disa JJ, Polvora VP, Pusic AL, Singh B, Cordeiro PG. Dextran-related complications in head and neck microsurgery: do the benefits outweigh the risks? A prospective randomized analysis. *Plast Reconstr Surg* 2003;112(06):1534–1539
- 65 Jayaprasad K, Mathew J, Thankappan K, et al. Safety and efficacy of low molecular weight dextran (dextran 40) in head and neck free flap reconstruction. *J Reconstr Microsurg* 2013;29(07):443–448
- 66 Ridha H, Jallali N, Butler PE. The use of dextran post free tissue transfer. *J Plast Reconstr Aesthet Surg* 2006;59(09):951–954
- 67 Riva FM, Chen YC, Tan NC, et al. The outcome of prostaglandin-E1 and dextran-40 compared to no antithrombotic therapy in head and neck free tissue transfer: analysis of 1,351 cases in a single center. *Microsurgery* 2012;32(05):339–343
- 68 Sun TB, Chien SH, Lee JT, Cheng LF, Hsu LP, Chen PR. Is dextran infusion as an antithrombotic agent necessary in microvascular reconstruction of the upper aerodigestive tract? *J Reconstr Microsurg* 2003;19(07):463–466
- 69 Hardin CK, Kirk WC, Pederson WC. Osmotic complications of low-molecular-weight dextran therapy in free flap surgery. *Microsurgery* 1992;13(01):36–38
- 70 Hein KD, Wechsler ME, Schwartzstein RM, Morris DJ. The adult respiratory distress syndrome after dextran infusion as an antithrombotic agent in free TRAM flap breast reconstruction. *Plast Reconstr Surg* 1999;103(06):1706–1708
- 71 Kaplan AI, Sabin S. Dextran 40: another cause of drug-induced noncardiogenic pulmonary edema. *Chest* 1975;68(03):376–377
- 72 Machado MA, Volpe P, Lima M das G, et al. [Anaphylaxis after dextran 40 infusion: report of a case and review of the literature]. *Rev Hosp Clin Fac Med Sao Paulo* 1993;48(04):167–169
- 73 Parry SW, Toth BA, Elliott LF. Microvascular free-tissue transfer in children. *Plast Reconstr Surg* 1988;81(06):838–840
- 74 Francis CW, Pellegrini VD Jr, Stulberg BN, Miller ML, Totterman S, Marder VJ. Prevention of venous thrombosis after total knee arthroplasty. Comparison of antithrombin III and low-dose heparin with dextran. *J Bone Joint Surg Am* 1990;72(07):976–982
- 75 Mätzsch T, Bergqvist D, Fredin H, Hedner U. Low molecular weight heparin compared with dextran as prophylaxis against thrombosis after total hip replacement. *Acta Chir Scand* 1990;156(6-7):445–450
- 76 Oertli D, Hess P, Durig M, et al. Prevention of deep vein thrombosis in patients with hip fractures: low molecular weight heparin versus dextran. *World J Surg* 1992;16(05):980–984, discussion 984–985
- 77 Feldman DS, Zuckerman JD, Walters I, Sakales SR. Clinical efficacy of aspirin and dextran for thromboprophylaxis in geriatric hip fracture patients. *J Orthop Trauma* 1993;7(01):1–5
- 78 Büller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest* 2004;126(3, Suppl):401S–428S
- 79 Jaggi R, Taylor SM, Trites J, Anderson D, MacDougall P, Hart RD. Review of thromboprophylaxis in otolaryngology-head and neck surgery. *J Otolaryngol Head Neck Surg* 2011;40(03):261–265
- 80 Gavriel H, Thompson E, Kleid S, Chan S, Sizeland A. Safety of thromboprophylaxis after oncologic head and neck surgery. Study of 1018 patients. *Head Neck* 2013;35(10):1410–1414
- 81 Moubayed SP, Eskander A, Mourad MW, Most SP. Systematic review and meta-analysis of venous thromboembolism in otolaryngology-head and neck surgery. *Head Neck* 2017;39(06):1249–1258
- 82 Ah-See KW, Kerr J, Sim DW. Prophylaxis for venous thromboembolism in head and neck surgery: the practice of otolaryngologists. *J Laryngol Otol* 1997;111(09):845–849
- 83 Pallister C, Watson M. *Haematology*. 2nd ed: Scion Publishing; 2010
- 84 Shuman AG, Hu HM, Pannucci CJ, Jackson CR, Bradford CR, Bahl V. Stratifying the risk of venous thromboembolism in otolaryngology. *Otolaryngol Head Neck Surg* 2012;146(05):719–724
- 85 Davison SP, Venturi ML, Attinger CE, Baker SB, Spear SL. Prevention of venous thromboembolism in the plastic surgery patient. *Plast Reconstr Surg* 2004;114(03):43E–51E
- 86 Young T, Aukes J, Hughes R, Tang H. Vena caval filters for the prevention of pulmonary embolism. *Cochrane Database Syst Rev* 2007;(03):CD006212
- 87 Robert F. The potential benefits of low-molecular-weight heparins in cancer patients. *J Hematol Oncol* 2010;3(01):3
- 88 Lee AYY, Levine MN, Baker RI, et al; Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. *N Engl J Med* 2003;349(02):146–153
- 89 Akl EA, Terrenato I, Barba M, et al. Low-molecular-weight heparin vs unfractionated heparin for perioperative thromboprophylaxis in patients with cancer: a systematic review and meta-analysis. *Arch Intern Med* 2008;168(12):1261–1269
- 90 Wikner J, Beck-Broichsitter BE, Schlesinger S, et al. Thromboelastometry: a contribution to perioperative free-flap management. *J Craniomaxillofac Surg* 2015;43(07):1065–1071
- 91 Benes J, Zatloukal J, Kletecka J. Viscoelastic methods of blood clotting assessment - a multidisciplinary review. *Front Med (Lausanne)* 2015;2:62
- 92 Luddington RJ. Thrombelastography/thromboelastometry. *Clin Lab Haematol* 2005;27(02):81–90
- 93 Wikkelsø A, Wetterslev J, Møller AM, Afshari A. Thromboelastography (TEG) or rotational thromboelastometry (ROTEM) to monitor haemostatic treatment in bleeding patients: a systematic review with meta-analysis and trial sequential analysis. *Anaesthesia* 2017;72(04):519–531